July 16, 2024 - Dr. A. Stylianou Unveils Groundbreaking AFM-Based Nanomechanical Biomarkers at the 29th Congress of the European Society of Biomechanics Edinburgh, Scotland – July 3, 2024 – Dr. A. Stylianou, leader of the Cancer Mechanobiology and Applied Biophysics Research Group at the Basic and Translational Cancer Research Center, delivered an influential perspective talk titled "AFM-based Nanomechanical Biomarkers" at the 29th Congress of the European Society of Biomechanics, held from June 30 to July 3, 2024.
In the presentation, Dr. Stylianou highlighted the revolutionary impact of Atomic Force Microscopy (AFM) in developing novel nanomechanical biomarkers. AFM stands out as a unique tool, allowing for the precise probing of biological samples at the nanoscale. This technique provides unprecedented insights into the mechanical properties of cells and tissues, thereby aiding in the quantification of these properties with exceptional precision.
"AFM is transforming our approach to biomechanics research by unveiling the intricate nanoscale mechanical properties of life," said Dr. Stylianou. "The development of AFM-based nanomechanical biomarkers is paving the way for innovative solutions in healthcare and beyond."
Recent advances in AFM technology underscore its transformative potential, emphasizing the need for further exploration in technology enhancement, data analysis, and collaborative research. These biomarkers are set to reshape our understanding of biology, offering new avenues for diagnosis and treatment of various physiological and pathological conditions.
This work was conducted under the project "MechanoLung" (EXCELLENCE/0421/0263). The project is implemented under the programme of social cohesion “THALIA 2021-2027” co-funded by the European Union, through Research and Innovation Foundation.
Contact Information
Andreas Stylianou
Cancer Mechanobiology And Applied Biophysics Research Group
